Biomedicines

Journal Browser

► Journal Browser

Special Issue Editors

Dr. Paola Tiberio

E-Mail Website
Guest Editor

Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano (Milan), Italy
Interests: breast cancer; neoadjuvant chemotherapy; supportive therapies; biomarkers; liquid biopsy

Dr. Rita De Sanctis

E-Mail Website
Co-Guest Editor

Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20090 Milan, Italy
Interests: breast cancer; neoadjuvant chemotherapy; pathological complete response; prognosis; predictive factors; microbiome; radiomics; headache disorders; quality of life; nomograms
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Breast cancer is a very heterogeneous disease with multifactorial etiopathogenesis. Over the last few decades, a deeper understanding of the molecular mechanisms underlying breast cancer development and progression has led to the development of novel accurate prognostic analyses and new effective drugs, thus leading to an increase in the overall survival of breast cancer patients. Nevertheless, breast cancer remains the second leading cause of death in women globally. Thus, there is still a need for a better comprehension of the complexity of breast cancer and the interaction between the neoplasm and its microenvironment as well as the immune system in order to prevent disease development and to guide personalized treatments. Moreover, since individual response to therapy and long-term prognosis remain highly unpredictable, the current scenario requires the identification of biomarkers that accurately forecast the response to therapy and identify patients who will not benefit from standard regimens. On the other hand, since the number of breast cancer survivors is continuously increasing, knowing the complexity of breast cancer survivorship is essential for adequate patient management.

Dr. Paola Tiberio
Guest Editor

Dr. Rita De Sanctis
Co-Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

breast cancer
diagnosis
prognosis
treatment response prediction
biomarkers, risk factors
new therapies

Published Papers (2 papers)

Download All Papers

Research

Jump to: Other

11 pages, 816 KiB

Open AccessArticle

Prognostic Value of Tumor Budding for Early Breast Cancer

by Diogo J. Silva, Gonçalo Miranda, Teresina Amaro, Matilde Salgado and Alexandra Mesquita

Biomedicines 2023, 11(11), 2906; https://doi.org/10.3390/biomedicines11112906 - 27 Oct 2023

Cited by 1 | Viewed by 1177

Abstract

Background: Tumor budding (TB) is a dynamic process associated with the epithelial–mesenchymal transition and a well-established prognostic biomarker for colorectal cancer. As part of the tumor microenvironment, tumor buds demonstrate increased cell motility and invasiveness. Current evidence demonstrates that high levels of TB correlate with disease progression and worst outcomes across different solid tumors. Our work aims to demonstrate the clinical applicability of TB analysis and its utility as a prognostic factor for patients with early breast cancer (EBC). Methods: Retrospective, single-center, observational study, enrolling patients with EBC diagnosed in a Portuguese hospital between 2014 and 2015. TB classification was performed according to the International Tumor Budding Conference 2016 guidelines. Results: A statistically significant relation was found between higher TB score and aggressive clinicopathological features (angiolymphatic/perineural invasion-p < 0.001; tumor size-p = 0.012; nuclear grading-p < 0.001; and Ki-67 index-p = 0.011), higher number of relapses (p < 0.001), and short disease-free survival (DFS) (p < 0.001). Conclusion: We demonstrate that high TB correlates with shorter DFS and aggressive clinicopathological features used in daily practice to decide on the benefit of chemotherapy for EBC. TB represents a needed prognostic biomarker for EBC, comprising a new factor to be considered in the adjuvant decision-making process by identifying patients at a high risk of relapse and with higher benefit on treatment intensification. Clinical trials incorporating TB are needed to validate its prognostic impact. Full article

(This article belongs to the Special Issue New Insights into Breast Cancer Management: From Tumorigenesis to Personalized Treatments)

► Show Figures

Figure 1

Other

Jump to: Research

11 pages, 4298 KiB

Open AccessCase Report

Takotsubo Syndrome during Pertuzumab and Trastuzumab Therapy for HER2-Positive Metastatic Breast Cancer

by Azzurra Irelli, Laura Ceriello, Leonardo Valerio Patruno, Alessandra Tessitore, Edoardo Alesse, Katia Cannita and Donatello Fabiani

Biomedicines 2024, 12(1), 179; https://doi.org/10.3390/biomedicines12010179 - 14 Jan 2024

Viewed by 935

Abstract

Pertuzumab and trastuzumab have been shown to improve the outcomes of patients with metastatic breast cancer, with a rate of left ventricular dysfunction of approximately 6%. We report the case of a postmenopausal woman who presented with Takotsubo syndrome during maintenance therapy with pertuzumab and trastuzumab, in association with fulvestrant (an anti-estrogen) and denosumab. After normalization of cardiac function, therapy with pertuzumab and trastuzumab was resumed in the absence of new cardiac toxicity. We report the first clinical case of Takotsubo syndrome during double anti-HER2 blockade in association with an antiestrogen. Furthermore, we show how anti-HER2 therapy can be safely resumed after the detection of Takotsubo syndrome. Full article

(This article belongs to the Special Issue New Insights into Breast Cancer Management: From Tumorigenesis to Personalized Treatments)

► Show Figures